Novel AI Model PROGRxN-BCa Significantly Improves NMIBC Progression Risk Prediction
- A new artificial intelligence model, PROGRxN-BCa, trained on over 12,000 patients, outperforms current guideline-endorsed risk calculators for non-muscle invasive bladder cancer progression by approximately 10%.
- The model effectively sub-stratifies the heterogeneous intermediate-risk NMIBC patient group into distinct risk tertiles, enabling more personalized treatment approaches based on progression probability.
- Developed using 14 readily available clinicopathological features, PROGRxN-BCa requires no specialized biomarkers or histopathological slides, making it practical for routine clinical implementation.